Second-line systemic treatment
ApprovedSmall molecule
Second-line systemic treatment is one of 25 small molecule programs targeting Atopic Dermatitis. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
508 competitors in Atopic Dermatitis
#DrugCompanyPhaseTrials
1Elidel
BayerPhase 3
Second-line systemic treatment
IInstituto de Investigación Hospital Universitario La Paz
Approved
LNK01001
LLynk Pharmaceuticals Co., Ltd
Phase 3
Adquey
AAcrotech Biopharma Inc.
Phase 3
EBGLYSS
Eli LillyPreclinical
Cibinqo
PfizerPreclinical
Product 0405
FFougera Pharmaceuticals Inc.
Phase 3
Prograf
VVeloxis Pharmaceuticals
Preclinical
Stapokibatrt
KKeymed Biosciences Co.Ltd
Phase 3
Adtralza
LEO PharmaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Atopic Dermatitis1 trial
Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models
Recruiting·IInstituto de Investigación Hospital Universitario La Paz·Phase 4·NCT06366932·150 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details